Second Generation FusionInhibitor T-1249

Expanding Treatment Options

• Rationally designed based on peptide sequence analysis

• Desirable biological properties
  • High potency
  • Broad spectrum of activity
  • Long-half-life

• In vitro activity against existing Fuzeon resistant isolates

• Phase I/II dose ranging study completed

• Phase II expected to begin in 2003

Previous slide

Next slide

Back to first slide

View graphic version